CEACAM5 and cholangiocarcinoma: Current blood-test screening techniques also have limitations as they rely on the detection of the biomarkers (e.g., carbohydrate antigen (CA19–9), carcinoembryonic antigen (CEA)), which are nonspecific to CCA, leading to insufficient diagnostic sensitivity and specificity [12].